Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced the addition of two novel assets that will expand the Company’s rare autoimmune and kidney-related disease pipeline.
Last month, I was chosen to speak on a panel with leaders in the biotech industry and we all had two things in common: a great appreciation for this emerging life sciences region along with office headquarters in Montgomery County, MD.
VICTORIA, British Columbia & ROCKVILLE, Md.–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) today, in recognition of World Lupus Day, affirmed its commitment to increasing access to equitable healthcare for individuals living with the autoimmune disease systemic lupus erythematosus (SLE) and lupus nephritis (LN) through the sponsorship of grants to establish community-focused patient navigator programs. LN is one of the most serious and common complications of SLE and affects significantly more Black, Asian, and Hispanic individuals living with SLE than non-Hispanic white individuals with the condition. If left untreated, LN can cause irreversible kidney damage and increases the risk of kidney failure, cardiac events, and death.
BioBuzz is proud to feature the all-female teams at Aurinia Pharmaceuticals and U.S. Pharmacopeia (USP) for Women’s History Month 2021.
The FDA greenlit Aurinia’s Lupkynis (voclosporin) in combination with a background immunosuppressive therapy regimen for LN, a serious progression of systemic lupus erythematosus (SLE), a chronic, complex and autoimmune disease. The approval not only marks the first medication in the United States specifically approved for active LN, it also marks the first for Aurinia, which is headquartered in Canada and last year opened its 30,000 square-foot commercialization facility in the BioHealth Capital Region.
In 2020 we introduced a new series titled “5 Questions With…” in an effort to spotlight individuals from across the BioHealth Capital Region and beyond. Providing this platform has allowed us to help share the stories of industry peers and show that there isn’t a single “right” way to becoming an industry success.
2020 found the United States embroiled in a chaotic political environment, reckoning with social unrest and racial injustice, and voting in one of the most consequential presidential elections in the country’s history.
Aurinia Pharmaceuticals (Aurinia) is a late-stage clinical biopharmaceutical company (Toronto Stock Exchange (TSX:AUP); NASDAQ (NASDAQ:AUPH) focused on commercializing therapies for rare autoimmune and inflammatory conditions.
Sara Nayeem, M.D. is a Partner at New Enterprise Associates (NEA), a large diversified venture capital firm. Sara joined NEA’s healthcare team in 2009 and focuses on investments in biopharmaceutical companies. She serves on the boards of Centrexion, Complexa, Cydan, Imara (IMRA), Tiburio, and a stealth targeted oncology company.
Former MedImmune Employees Leading In the BioHealth Capital Region and Beyond In a recent conversation someone shared the quote “You can’t throw a stone in the BioHealth Capital Region and [….]
